Literature DB >> 13678554

Hallucinogens: an update.

John H Halpern1.   

Abstract

Research of hallucinogen abuse rarely extends beyond epidemiology and observed pathology. Even less research has been completed on the special circumstances surrounding the religious use of hallucinogens or on potential therapeutic applications. Rather than offer another basic review on the well-known hazards of illicit hallucinogen use, this paper provides an overview and practice recommendations on compounds the clinician may be less familiar with, such as the botanical plant Salvia divinorum, the drug 3,4-methylenedioxymethamphetamine ("ecstasy") and synthetic hallucinogen analogs. The often-warned, but rarely occurring, hazard of hallucinogen persisting perception disorder ("flashbacks") is also reviewed with treatment recommendations provided. The current status of clinical research with the hallucinogens is presented, with case vignettes suggesting hallucinogens may have anti-addictive applications. The special circumstances surrounding the religious, nondrug use of hallucinogens as sacred sacraments in the US and elsewhere are also presented. It is hoped that the reader will gain a more nuanced understanding of how these physiologically nonaddictive drugs may offer legitimate benefits in modern society. By appreciating that such benefits may one day be borne out by careful, methodologically sound research, clinicians should be better armed in raising the topic of hallucinogen use and abuse with their patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678554     DOI: 10.1007/s11920-003-0067-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  36 in total

1.  The 'sextasy' craze. Clubland's dangerous party mix: Viagra and ecstasy.

Authors:  Karen Breslau
Journal:  Newsweek       Date:  2002-06-03

2.  MDMA ("Ecstasy") abuse and high-risk sexual behaviors among 169 gay and bisexual men.

Authors:  R L Klitzman; H G Pope; J I Hudson
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

3.  LSD-assisted psychotherapy with terminal cancer patients.

Authors:  W N Pahnke; A A Kurland; L E Goodman; W A Richards
Journal:  Curr Psychiatr Ther       Date:  1969

4.  Inhibitory effects of ibogaine on cocaine self-administration in rats.

Authors:  S L Cappendijk; M R Dzoljic
Journal:  Eur J Pharmacol       Date:  1993-09-14       Impact factor: 4.432

5.  Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties.

Authors:  K K Szumlinski; R E Haskew; M Y Balogun; I M Maisonneuve; S D Glick
Journal:  Pharmacol Biochem Behav       Date:  2001 Jul-Aug       Impact factor: 3.533

Review 6.  Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

Review 7.  Hallucinogen persisting perception disorder: what do we know after 50 years?

Authors:  John H Halpern; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

Review 8.  Adverse reactions to psychedelic drugs. A review of the literature.

Authors:  R J Strassman
Journal:  J Nerv Ment Dis       Date:  1984-10       Impact factor: 2.254

Review 9.  Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.

Authors:  L J Valdés
Journal:  J Psychoactive Drugs       Date:  1994 Jul-Sep

10.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.

Authors:  R Thomasius; K Petersen; R Buchert; B Andresen; P Zapletalova; L Wartberg; B Nebeling; A Schmoldt
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

View more
  6 in total

1.  Culture, psychosomatics and substance abuse: the example of body image drugs.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Psychother Psychosom       Date:  2012-01-18       Impact factor: 17.659

Review 2.  Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.

Authors:  Sam G Moreton; Luke Szalla; Rachel E Menzies; Andrew F Arena
Journal:  Psychopharmacology (Berl)       Date:  2019-11-29       Impact factor: 4.530

Review 3.  The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  2007-02-13       Impact factor: 4.530

4.  Hallucinogen-persisting perception disorder.

Authors:  Leo Hermle; Melanie Simon; Martin Ruchsow; Martin Geppert
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

5.  Developmental trajectories of illicit drug use, prescription drug misuse and cannabis practices among young adult cannabis users in Los Angeles.

Authors:  Ekaterina V Fedorova; Sheree M Schrager; Lucy F Robinson; Alexis M Roth; Carolyn F Wong; Ellen Iverson; Stephen E Lankenau
Journal:  Drug Alcohol Rev       Date:  2020-05-10

6.  Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.

Authors:  James D Sexton; Charles D Nichols; Peter S Hendricks
Journal:  Front Psychiatry       Date:  2020-02-11       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.